Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q2 FY20 results · Jul–Sep 2019
Procter & Gamble Health reported revenue from operations of ₹225.17 crore (down 0.4% from Q2 FY19) and net profit of ₹35.76 crore (down 31.7% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a standalone basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 225.17 | 226.15 | −0.4% | 233.63 | −3.6% |
| Other income | 6.72 | 6.07 | +10.8% | 17.47 | −61.5% |
| Total income | 231.89 | 232.22 | −0.1% | 251.11 | −7.7% |
| Profit before tax | 52.58 | 59.94 | −12.3% | 67.50 | −22.1% |
| Net profit for the period | 35.76 | 52.33 | −31.7% | 44.08 | −18.9% |
| EPS, basic (₹) | 21.54 | 31.52 | −31.7% | 26.56 | −18.9% |
| Net margin (%) | 15.9 | 23.1 | 18.9 |
Standalone
- Filed with BSE
- 08 Nov 2019, 11:58 IST
- Board meeting
- 07 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE